Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Refametinib and sorafenib in RAS-mutant HCC
NCT01915602Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2013
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of refametinib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Sep 2013; status: completed.
02
Drugs
refametinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01915602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01915602.